Disc Medicine, Inc. (NASDAQ:IRON) Director Mona Ashiya Sells 39,656 Shares

Disc Medicine, Inc. (NASDAQ:IRON - Get Free Report) Director Mona Ashiya sold 39,656 shares of the firm's stock in a transaction dated Wednesday, March 19th. The stock was sold at an average price of $54.02, for a total value of $2,142,217.12. Following the completion of the sale, the director now directly owns 188,981 shares in the company, valued at $10,208,753.62. The trade was a 17.34 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Mona Ashiya also recently made the following trade(s):

• On Friday, March 21st, Mona Ashiya sold 10,011 shares of Disc Medicine stock. The stock was sold at an average price of $54.00, for a total transaction of $540,594.00.
• On Wednesday, March 12th, Mona Ashiya sold 83,182 shares of Disc Medicine stock. The stock was sold at an average price of $54.45, for a total transaction of $4,529,259.90.
• On Monday, March 10th, Mona Ashiya sold 202,146 shares of Disc Medicine stock. The shares were sold at an average price of $54.29, for a total value of $10,974,506.34.

Disc Medicine Stock Down 1.7 %

IRON traded down $0.91 during midday trading on Tuesday, hitting $52.79. 182,245 shares of the company traded hands, compared to its average volume of 360,626. The company's 50-day moving average is $55.06 and its 200 day moving average is $56.15. The firm has a market capitalization of $1.82 billion, a PE ratio of -13.26 and a beta of 0.73. Disc Medicine, Inc. has a 52 week low of $25.60 and a 52 week high of $68.73.

Remove Ads

Disc Medicine (NASDAQ:IRON - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.98) earnings per share for the quarter, beating analysts' consensus estimates of ($1.06) by $0.08. On average, sell-side analysts predict that Disc Medicine, Inc. will post -4.07 earnings per share for the current fiscal year.

Institutional Trading of Disc Medicine

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in IRON. Sterling Capital Management LLC grew its position in shares of Disc Medicine by 798.4% during the 4th quarter. Sterling Capital Management LLC now owns 566 shares of the company's stock valued at $36,000 after acquiring an additional 503 shares during the period. GF Fund Management CO. LTD. purchased a new position in Disc Medicine during the fourth quarter valued at $40,000. Tower Research Capital LLC TRC lifted its position in Disc Medicine by 47.6% during the fourth quarter. Tower Research Capital LLC TRC now owns 825 shares of the company's stock valued at $52,000 after purchasing an additional 266 shares in the last quarter. Quest Partners LLC bought a new stake in Disc Medicine during the third quarter valued at about $131,000. Finally, Quantbot Technologies LP purchased a new stake in Disc Medicine in the third quarter worth about $146,000. 83.70% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

IRON has been the topic of a number of analyst reports. Cantor Fitzgerald boosted their price target on Disc Medicine from $99.00 to $132.00 and gave the stock an "overweight" rating in a research report on Tuesday, March 18th. Wedbush reissued an "outperform" rating and issued a $90.00 target price (up from $83.00) on shares of Disc Medicine in a report on Tuesday, January 21st. Stifel Nicolaus raised their price target on Disc Medicine from $90.00 to $94.00 and gave the company a "buy" rating in a report on Friday, January 24th. Morgan Stanley reaffirmed an "overweight" rating and issued a $85.00 price target on shares of Disc Medicine in a research report on Friday, March 7th. Finally, TD Cowen started coverage on shares of Disc Medicine in a research report on Thursday, February 27th. They set a "buy" rating on the stock. Ten equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Disc Medicine has a consensus rating of "Buy" and a consensus target price of $93.80.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.